Valuation: Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.

Market Cap 14.53B 2.14B 1.87B 1.73B 1.59B 3B 206B 3.07B 20.67B 8.13B 101B 8.05B 7.88B 348B P/E 2026 *
111x
P/E 2027 * 103x
Enterprise Value 14.53B 2.14B 1.87B 1.73B 1.59B 3B 206B 3.07B 20.67B 8.13B 101B 8.05B 7.88B 348B EV / Sales 2026 *
19x
EV / Sales 2027 * 14.6x
Free-Float
65.55%
Yield 2026 *
-
Yield 2027 * -
May. 19 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Approves Final Cash Dividend on A Shares for 2025, Payable on 16 July 2026 CI
Apr. 23 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 21 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. announced that it expects to receive CNY 300 million in funding CI
Mar. 31 Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 24, 2025. CI
Mar. 01 Hainan Lingqing Digital Pharmaceutical Technology Co., Ltd. announced that it has received CNY 450 million in funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. CI
Feb. 28 Kemai Biotech Co., Ltd. announced that it has received funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd., Wuxi Capital Group Co.,Ltd, XtalPi Holdings Limited CI
Jan. 20 Hainan Lingqing Digital Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 450 million in funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. CI
Jan. 08 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. entered into a Share Transfer Agreement to acquire 35% stake in Ningbo Guangfeng Capsule Co., Ltd. from Ningbo Sprague Biotechnology Co., Ltd. for CNY 8.5 million. CI
Jan. 05 Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 24, 2025. CI
25-10-22 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-10-09 Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 24, 2025. CI
25-08-26 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-24 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
1 day-7.14%
1 week-17.66%
Current month-34.70%
1 month-31.80%
3 months+17.12%
6 months+28.73%
Current year+73.32%
1 week 67.9
Extreme 67.9
81.52
1 month 67.9
Extreme 67.9
110.32
Current year 36.19
Extreme 36.1923
110.32
1 year 19.62
Extreme 19.6154
110.32
3 years 10.13
Extreme 10.1302
110.32
5 years 10.13
Extreme 10.1302
110.32
10 years 10.13
Extreme 10.1302
110.32
Manager TitleAgeSince
Chief Executive Officer 44 2009-10-15
Director of Finance/CFO 53 2019-06-15
Corporate Officer/Principal 63 2009-10-15
Director TitleAgeSince
Director/Board Member 47 2022-03-21
Director/Board Member 69 2009-10-15
Chairman 44 2022-03-21
Date Insider Type Main position Quantity % Market Cap.
4/20/26 Buy

Chief Executive Officer

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-17.66%+222.89%+243.80% 2.14B
+0.65%+4.48%+24.47%+28.25% 28.7B
-0.46%+0.66%+7.93%+23.62% 27.43B
-1.78%-0.01%+79.47%+144.20% 7.35B
-1.74%+8.84%+2.19%+16.93% 6.3B
-0.29%-0.27%+5.33% - 6.12B
-1.82%-2.94%-2.30%+36.87% 4.52B
-0.47%+2.43%+29.83%+110.86% 3.79B
0.00%+0.38%+32.41%+56.35% 3.6B
-8.42%+5.96%+81.99%+65.26% 2.41B
Average -2.15%+1.85%+48.42%+80.68% 9.24B
Weighted average by Cap. -0.71%+2.17%+26.47%+47.48%

Financials

2026 *2027 *
Net sales 763M 113M 98.43M 90.83M 83.72M 158M 10.85B 161M 1.09B 427M 5.31B 423M 414M 18.29B 995M 147M 128M 118M 109M 206M 14.14B 210M 1.42B 557M 6.93B 551M 539M 23.84B
Net income 131M 19.4M 16.95M 15.64M 14.42M 27.17M 1.87B 27.78M 187M 73.53M 915M 72.84M 71.24M 3.15B 141M 20.77M 18.16M 16.75M 15.44M 29.11M 2B 29.75M 200M 78.76M 980M 78.02M 76.31M 3.37B
Net Debt - -
Logo Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.
Jiangsu Hualan New Pharmaceutical Material Co Ltd is a China-based company primarily engaged in the research, development, production and sales of packaging materials for injectable pharmaceuticals that come into direct contact with the drug. The Company’s main products include various types of coated rubber stoppers and conventional rubber stoppers. The Company also produces rubber components for pen syringes (cassette vials), assemblies for plastic infusion containers, silicone rubber products, medical devices, and accessories. The Company's pharmaceutical rubber stoppers are used to encapsulate various types of injectable drugs, vaccines, biological agents, antibiotics, infusions, blood collection containers, and anti-tumor drugs. The Company distributes its products within the domestic market and to overseas markets.
Employees
945
Date Price Change Volume
26-07-17 CN¥68.13 -7.14% 6,555,202
26-07-16 CN¥73.37 -8.29% 4,591,714
26-07-15 CN¥80.00 +3.93% 6,072,765
26-07-14 CN¥76.98 +3.27% 4,640,579
26-07-13 CN¥74.54 -9.92% 5,106,226
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
68.13CNY
Average target price
68.05CNY
Spread / Average Target
-0.11%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 301093 Stock